

pDRIVE-PSA-hPSA

A plasmid with a composite promoter based on the human Prostate Specific Antigen enhancer/promoter

Catalog # pdrive-psa-hpsa

For research use only

Version # 01E02-MT

PRODUCT INFORMATION

Content:

- 1 disk of lyophilized GT100 *E. coli* bacteria transformed by a pDRIVE plasmid.
- GT100 genotype is: *F*-, *mcrA*, Δ (*mrr-hsdRMS-mcrBC*), \emptyset 80*lacZ* Δ M15, Δ *lacX74*, *recA1*, *endA1*.
- 4 pouches of *E. coli* FastMedia™ Zeo

Shipping and storage:

- Products are shipped at room temperature.
- Transformed bacteria should be stored at -20°C. Bacteria are stable up to one year when properly stored.
- Store *E. coli* FastMedia™ Zeo at room temperature. FastMedia™ is stable 18 months when stored properly.

Quality control:

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Bacteria have been lyophilized, and their viability upon resuspension has been verified.
- Promoter activity has been confirmed by transient transfection of 293 cells as well as other selected cell lines.

GENERAL PRODUCT USE

pDRIVE is an expression plasmid containing a native or composite promoter of interest. pDRIVE may be used to:

- **Subclone a promoter of interest into another vector.** Unique restriction sites are present at each end of the promoter allowing convenient excision. The 5' sites include *Sda* I, *Pst* I, and *Spe* I. *Sda* I is compatible with *Nsi* I and *Pst* I. *Spe* I is compatible with *Avr* II, *Nhe* I and *Xba* I. The 3' restriction site is *Nco* I which includes the ATG start codon, and is compatible with *Bsp*H I and *Bsp*LU11 I.
- **Compare the activity of different promoters** in transient transfection experiments. Each pDRIVE promoter drives the expression of the *LacZ* reporter gene which allows for testing of the promoter's activity in transient transfection experiments. Furthermore, the *LacZ* gene is flanked by unique restriction sites (*Nco* I and *Eco*R I) for easy replacement with a different gene of interest.

COMPOSITE PROMOTER CHARACTERISTICS

Element	Name	Origin	Size bp
Promoter	PSA	Human	625
5' UTR	PSA	Human	42
Enhancer	PSA	human	1590

PSAenhancer/promoter

Prostate specific antigen (PSA) or KLK3 is a serine protease which is synthesized primarily by both normal prostate epithelium and the vast majority of prostate cancers. The expression of PSA is mainly induced by androgens at the transcriptional level via the androgen receptor (AR). The AR modulates transcription through its interaction with its consensus DNA binding site, GGTACAnnnTGTT/CCT, termed the androgen response element (ARE)¹. The core PSA promoter region exhibits low activity and specificity, but inclusion of the PSA enhancer sequence which contains a putative ARE increases expression, specifically in PSA-positive cells. Expression can be further increased when induced with androgens such as dihydrotestosterone².

PLASMID FEATURES

- **LacZ gene** encodes β -galactosidase an enzyme that catalyzes the hydrolysis of X-Gal, producing a blue precipitate that can be easily visualized under a microscope.
 - **SV40 pAn:** The Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA.
 - **Ori pMB1** is a minimal *E. coli* origin of replication with the same activity as the longer Ori.
 - **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
 - **Sh ble** gene confers zeocin resistance therefore allowing the selection of transformed *E. coli* carrying a pDRIVE plasmid.
- Note: Stable transfection of clones cannot be performed due to the absence of an eukaryotic promoter upstream of the Sh ble gene.*

METHODS

Growth of pDRIVE-transformed bacteria:

Use sterile conditions to do the following:

- 1- Resuspend the lyophilized *E. coli* by adding 1 ml of LB medium in the tube containing the disk. Let sit for 5 minutes. Mix gently by inverting the tube several times.
- 2- Streak bacteria taken from this suspension on a zeocin LB agar plate prepared with the *E. coli* FastMedia™ Zeo agar provided (see below).
- 3- Place the plate in an incubator at 37°C overnight.
- 4- Isolate a single colony and grow the bacteria in TB supplemented with zeocin using the FastMedia™ Zeo liquid provided (see below).
- 5- Extract the pDRIVE plasmid DNA using the method of your choice.

Selection of bacteria with *E. coli* FastMedia™ Zeo:

E. coli FastMedia™ Zeo is a **new, fast and convenient** way to prepare liquid and solid media for bacterial culture by using only a microwave. *E. coli* FastMedia™ Zeo is a TB (liquid) or LB (solid) based medium with zeocin, and contains stabilizers.

E. coli FastMedia™ Zeo can be ordered separately (catalog code # fas-zn-1, fas-zn-s).

Method:

- 1- Pour the contents of a pouch into a clean borosilicate glass bottle or flask.
- 2- Add 200 ml of distilled water to the flask
- 3- Heat in a microwave on MEDIUM power setting (about 400Watts), until bubbles start appearing (approximately 3 minutes). **Do not heat a closed container. Do not autoclave FastMedia™.**
- 4- Swirl gently to mix the preparation. **Be careful, the bottle and media are hot, use heatproof pads orgloves and care when handling.**
- 5- Reheat the media for 30 seconds and gently swirl again. Repeat as necessary to completely dissolve the powder into solution. But be careful to avoid overboiling and volume loss.
- 6- Let agar medium cool to 45°C before pouring plates. Let liquid media cool to 37°C before seeding bacteria.

Note: Do not reheat solidified FastMedia™ as the antibiotic will be permanently destroyed by the procedure.

References:

- 1- Eric R. Schuur et al. 1996. JBC. 271(12):7043-7051
- 2- Latham JP et al. 2000. Cancer Res. 60(2):334-41

TECHNICAL SUPPORT

Toll free (US): 888-457-5873


Outside US: (+1) 858-457-5873

E-mail: info@invivogen.com

Website: www.invivogen.com



3950 Sorrento Valley Blvd. Suite A
San Diego, CA92121 - USA



TECHNICAL SUPPORT

Toll free (US): 888-457-5873
 Outside US: (+1) 858-457-5873
 E-mail: info@invivogen.com
 Website: www.invivogen.com



3950 Sorrento Valley Blvd. Suite A
 San Diego, CA92121 - USA

StuI (9)
SdaI (7) XbaI (12)

1 CCTGCAGGCCTCTAGAAATCTAGCTGATATAGTGTGGCTCAAACCTTCAGCACAAATCACACCGTTAGACTATCTGGTGTGGCCAAACCTTCAGGTGA
101 ACAAAAGGCACTCTAATCTGGCAGGATATTCCAAAGCATTAGAGATGACCTCTTGCAAAGAAAAAGAAATGGAAAAGAAAAAGAAAGAAAAA
201 AAAAAAAGAGATGACCTCTCAGGCTCTGAGGGGAAACGCTGAGGTCTTTGAGCAAGGTCACTCTCTGTTGCACAGTCTCCCTCACAGGGTCATTGTG
301 ACGATCAAATGTGGTCACGTGTATGAGGCACCAGCACATGCCTGGCTCTGGGGAGTGCCTGTAAGTGTATGCTTGCAGTCTGTAATGGCTGGGATGTGT
401 CAGGGATTATCTTCAGCACTTACAGATGCTCATCTCATCCTCACAGCATCACTATGGGATGGGTATTACTGGCTCATTTGATGGAGAAAGTGGCTGTGG
501 CTCAGAAAGGGGGACCCTAGACCAGGGACTCTGGATGCTGGGGACTCCAGAGACCATGACCACTACCAACTGCAGAGAAATTAATTGTGGCCTGA
601 TGTCCCTGCTCGAGAGGGTGGAGGTGGACCTTACTAACCTCTACCTTGACCTCTCTTTAGGGCTCTTTCTGACCTCCACCATGATACTAGGACC
701 CCATTGTATTCTGTACCCTCTTGACTCTATGACCCCCACTGCCACTGCATCCAGCTGGGTCCCTCTATCTTATCCAGCTGGCCAGTGCAGTCTC
801 AGTGCCACCTGTTTGTCAAGTAACTCTGAAGGGGCTGACATTTACTGACTTGCAAACAAATAAGCTAACTTCCAGAGTTTTGTGAATGCTGGCAGAGT
901 CCATGAGACTCTGAGTCAGAGCAAAGGCTTTACTGCTCACAGCTTAGCAGACAGCATGAGGTTTATGTTTCAATTAGTACACTTGCCCCCCCCAA
1001 ATCTTGTAGGGTGACCAGAGCAGTCTAGGTGGATGCTGTGCACAGGGGTTTGTCCACTGGTGAGAAACCTGAGATTAGGAATCCTCAATCTTATACTG
1101 GGACAACTTGCAAACCTGCTCAGCCTTTGTCTCTGATGAAGATATTATCTTCATGATCTTGGATTGAAAACAGACCTACTCTGGAGGAACATATTGTATC
1201 GATTGCTCTTGACAGTAAACAAATCTGTTGTAAGAGACATTATCTTTATTATCTAGGACAGTAAGCAAGCCTGGATCTGAGAGAGATATCATCTTGAAG
1301 GATGCCTGCTTTACAAACATCCTTGAACAACAATCCAGAAAAAAAAGGTGTGTCTTTGCTCAGAAGACACACAGATACGTGACAGAACCATGGA NcoI (1395)
1401 GAATTGCCTCCCAACGCTGTTCCAGCCAGACGCTTCCACCCTGTCTGCAGGACAGTCTCAACGTTCCACCATTAAATACTTCTTCTATCACATCCTGCTT
1501 CTTTATGCCTAACCAAGTTCTAGGTCCCGATCGACTGTGTCTGGCAGCACTCCACTGCCAAACCCAGAATAAGGCAGCGCTCAGGATCCCGACTAGTAC SpeI (1594)
1601 ATTGTTTGTGCACGTTGGATTTTGAATGCTAGGAACTTTGGGAGACTCATATTTCTGGGTAGAGGATCTGTGGACCACAAGATCTTTTATGATGA
1701 CAGTAGCAATGTATCTGTGGAGCTGGATTCTGGGTTGGGAGTGAAGGAAAAGAAATGTAATAAAGCAAGACATCTATTTCCAGGAGCATGAGGAATAAA
1801 AGTTCTAGTTTCTGGTCTCAGAGTGGTGCAGGGATCAGGGAGTCTACAATCTCCTGAGTGTGGTGTCTTAGGGCACACTGGGTCTGGAGTGCAAAGG
1901 ATCTAGGCACGTGAGGCTTTGTATGAAGAATCGGGGATCGTACCACCCCTGTTTCTGTTTCATCCTGGGCGTGTCTCCTCTGCCTTTGTCCCCTAGAT
2001 GAAGTCTCCATGAGCTACAGGGCTGGTGCATCCAGGGTATCTAGTAATTGCAGAACAGCAAGTGCTAGCTCTCCCTCCCCTCCACAGCTCTGGGTGT
2101 GGGAGGGGTTGTCCAGCCTCCAGCAGCATGGGAGGGCCTTGGTCCAGCTCTGGGTGCCAGCAGGGCAGGGGCGGAGTCTGGGGAATGAAGGTTTTAT
2201 AGGGCTCCTGGGGAGGCTCCCGAGCCCAAGCTTACCACCTGCACCCGAGAGCTGTGTCCATGGGGGTTCTCATCATCATCATCATGGTATG NcoI (2264)
13> MetGlyGlySerHisHisHisHisHisHisGlyMet
2301 GCTAGCATGACTGGTGGACAGCAAATGGGTGGGATCTGTACGACGATGACGATAAGGTACCTAAGGATCAGCTTGGAGTTGATCCCGTCTGTTTACAA
13> AlaSerMetThrGlyGlyGlnGlnMetGlyArgAspLeuTyrAspAspAspAspLysValProLysAspGlnLeuGlyValAspProValValLeuGlnA
2401 GTCGTGACTGGGAAAACCTGGCGTTACCAACTTAATCGCCTTGACGACATCCCCCTTCCGACGCTGGCGTAATAGCGAAGAGGCCCGCACCAGTGC
46> rgArgAspTrpGluAsnProGlyValThrGlnLeuAsnArgLeuAlaAlaHisProPheAlaSerTrpArgAsnSerGluGluAlaArgThrAspAr
2501 CCCTTCCAACAGTTGCGCAGCCTGAATGGGGAATGGCGCTTTGCTGGTTTCCGGCACCAGAAGCGGTGCCGGAAGCTGGCTGGAGTGGGATCTTCCT
79> gProSerGlnGlnLeuArgSerLeuAsnGlyGluTrpArgPheAlaTrpPheProAlaProGluAlaValProGluSerTrpLeuGluCysAspLeuPro
2601 GAGGCCGATACTGCTGCTGCCCTCAAACCTGGCAGATGCACGGTTACGATGCGCCATCTACACCAACGTAACCTATCCCATTACGGTCAATCCGCGCT
113> GluAlaAspThrValValValProSerAsnTrpGlnMetHisGlyTyrAspAlaProIeTyrThrAsnValThrTyrProlIeThrValAsnProP
2701 TTGTTCCACGGAGAATCCGACGGTTGTTACTCGCTCACATTTAATGTTGATGAAAGCTGGCTACAGGAAGGCCAGACGCGAATATTTTGTATGGCGT
146> heValProThrGluAsnProThrGlyCysTyrSerLeuThrPheAsnValAspGluSerTrpLeuGlnGluGlyGlnThrArgIleIlePheAspGlyVa
2801 TAACTCGGCGTTTCATCTGTGGTGAACGGGGCTGGTTCGGTTACGGCCAGGACAGTCTGTTTCCGCTCTGAATTTGACCTGAGCGCATTTTACGGCC
179> lAsnSerAlaPheHisLeuTrpCysAsnGlyArgTrpValGlyTyrGlyGlnAspSerArgLeuProSerGluPheAspLeuSerAlaPheLeuArgAla
2901 GGAGAAAACCGCTCGCGGTGATGGTGTGCTGCTGGAGTACGGCAGTTATCTGGAAGATCAGGATATGTGGCGGATGAGCGGCATTTTCCGTGACGCT
213> GlyGluAsnArgLeuAlaValMetValLeuArgTrpSerAspGlySerTyrLeuGluAspGlnAspMetTrpArgMetSerGlyIlePheArgAspValS
3001 CGTTGCTGCATAAACCGACTACACAAATCAGCGATTTCCATGTTGCCACTCGCTTAAATGATGATTTCCAGCCGCGTGTACTGGAGGCTGAAGTTCCAGAT
246> erLeuLeuHisLysProThrThrGlnIleSerAspPheHisValAlaThrArgPheAsnAspAspPheSerArgAlaValLeuGluAlaGluValGlnMe
3101 GTGCGGCGAGTTGCGTACTACCTACGGGTAACAGTTTCTTTATGGCAGGGTGAACCGCAGGTCGCCAGCGGCACCGCGCTTTCGGCGGTGAAATATC
279> tCysGlyGluLeuArgAspTyrLeuArgValThrValSerLeuTrpGlnGlyGluThrGlnValAlaSerGlyThrAlaProPheGlyGlyGluIleIle
3201 GATGAGCGTGGTGGTTATGCCGATCCGCTCACACTACGCTGGAACGTCGAAAACCGAACTGTGGAGCGCCGAAATCCCGAATCTCTATCGTCCGCTGG
313> AspGluArgGlyGlyTyrAlaAspArgValThrLeuArgLeuAsnValGluAsnProLysLeuTrpSerAlaGluIleProAsnLeuTyrArgAlaValV
3301 TTGAAGTGCACACCGCCGACGGCAGCTGATTGAAGCAGAAGCCTGGATGTCGGTTTCCGGAGGTTGAAATGGTCTGCTGCTGCTGAACGG
346> alGluLeuHisThrAlaAspGlyThrLeuIleGluAlaGluAlaCysAspValGlyPheArgGluValArgIleGluAsnGlyLeuLeuLeuLeuAsnGl
3401 CAAGCCGTTGCTGATTCGAGCGGTTAACCGTACGAGCATCATCCTGTCATGGTCAAGTATGATGAGCAGACGATGGTGCAGGATATCTGCTGATG
379> yLysProLeuLeuIleArgGlyValAsnArgHisGluHisHisProLeuHisGlyGlnValMetAspGluGlnThrMetValGlnAspIleLeuLeuMet

3501 AAGCAGAACAACCTTAACGCCGTGCGCTGTTCCGATTATCCGAACCATCCGCTGTGGTACACGCTGTGCGACCGCTACGGCCTGTATGTGGTGGATGAAG
413 LysGlnAsnAsnPheAsnAlaValArgCysSerHisTyrProAsnHisProLeuTrpTyrThrLeuCysAspArgTyrGlyLeuTyrValValAspGluA
3601 CCAATATTGAAACCCACGGCATGGTGGCAATGAATCGCTGACCGATGATCCGGCTGGCTACCGGGATGAGCGAACCGCTAACCGGAATGGTGCAGCG
446 laAsnI leGluThrHisGlyMetValProMetAsnArgLeuThrAspAspProArgTrpLeuProAlaMetSerGluArgValThrArgMetValGlnAr
3701 CGATCGTAATCACCCGAGTGTGATCATCTGGTGGCTGGGGAATGAATCAGGCCACGGCGCTAATCACGACCGCTGTATCGCTGGATCAAATCTGTCGAT
479 gAspArgAsnHisProSerValI leI leTrpSerLeuGlyAsnGluSerGlyHisGlyAlaAsnHisAspAlaLeuTyrArgTrpI leLysSerValAsp
3801 CCTTCCCGCCGGTGCAGTATGAAGGCGGGAGCCGACACCAGGCCACCGATATTATTTGCCGATGTACGCGCGCTGGATGAAGACCAGCCCTTCC
513 ProSerArgProValGlnTyrGluGlyGlyGlyAlaAspThrThrAlaThrAspI leI leCysProMetTyrAlaArgValAspGluAspGlnProPheP
3901 CGCTGTGCCAAATGGTCCATCAAAAATGGCTTTCGCTACCTGGAGAGACGCGCCGCTGATCCTTTGCCAATACGCCACGCGATGGGTAAACAGTCT
546 roAlaValProLysTrpSerI leLysLysTrpLeuSerLeuProGlyGluThrArgProLeuI leLeuCysGluTyrAlaHisAlaMetGlyAsnSerLe
4001 TGGCGTTTCGCTAAACTCGCAGCGGCTTCGTCAGTATCCCGTTACAGGGCGGTTTCGCTGGGACTGGGTGGATCAGTCGCTGATTAATATGAT
579 uGlyGlyPheAlaLysTyrTrpGlnAlaPheArgGlnTyrProArgLeuGlnGlyGlyPheValTrpAspTrpValAspGlnSerLeuI leLysTyrAsp
4101 GAAAACGGCAACCCGTTGGTTCGGCTTACGGCGGTGATTTTGGCGATACGCCGAACGATCGCCAGTCTGTATGAACGGTCTGGTCTTTGCCGACCGCACGC
613 GluAsnGlyAsnProTrpSerAlaTyrGlyGlyAspPheGlyAspThrProAsnAspArgGlnPheCysMetAsnGlyLeuValPheAlaAspArgThrP
4201 CGCATCCAGCGCTGACGGAAGCAAAACACCAGCAGCAGTTTTTCCAGTTCGTTTATCCGGGCAAACCATCGAAGTGACCAGCGAATACCTGTTCCGTC
646 roHisProAlaLeuThrGluAlaLysHisGlnGlnGlnPhePheGlnPheArgLeuSerGlyGlnThrI leGluValThrSerGluTyrLeuPheArgHi
4301 TAGCGATAACGAGCTCCTGCACTGGATGGTGGCGCTGGATGGTAAGCCGCTGGCAAGCGGTGAAGTGCCTCTGGATGCGCTCCACAAGGTAACAGTTG
679 sSerAspAsnGluLeuLeuHisTrpMetValAlaLeuAspGlyLysProLeuAlaSerGlyGluValProLeuAspValAlaProGlnGlyLysGlnLeu
4401 ATTGAACGCTGCAACTACCGCAGCCGAGAGCGCCGGCAACTCTGGCTCAGAGTACGCGTAGTGCACCGAACCGACCGCCATGGTCAGAAGCCGGGC
713 I leGluLeuProGluLeuProGlnProGluSerAlaGlyGlnLeuTrpLeuThrValArgValValGlnProAsnAlaThrAlaTrpSerGluAlaGlyH
4501 ACATCAGCGCTGGCAGCAGTGGCGTGGCGGAAAGCTCAGTGTGACGCTCCCGCGCGTCCACGCGCATCCCGCATCGACCACGCGAAATGGA
746 isI leSerAlaTrpGlnGlnTrpArgLeuAlaGluAsnLeuSerValThrLeuProAlaAlaSerHisAlal leProHisLeuThrThrSerGluMetAs
4601 TTTTTCATCGAGCTGGTAATAAGCGTTGGCAATTTAACGCCAGTCAAGCTTCTTTACAGATGTTGGATTGGCGATAAAAAACAACCTGCTGACGCCG
779 pPheCysl leGluLeuGlyAsnLysArgTrpGlnPheAsnArgGlnSerGlyPheLeuSerGlnMetTrpI leGlyAspLysLysGlnLeuLeuThrPro
4701 CTGCGGATCAGTTCACCCGTGCACCGCTGGATAACGACATTTGGCGTAAGTGAAGCGACCCGATTGACCCTAACGCTGGTTCGAACGCTGGAAGCGCG
813 LeuArgAspGlnPheThrArgAlaProLeuAspAsnAspI leGlyValSerGlyAlaThrArgI leAspProAsnAlaTrpValGluArgTrpLysAlaA
4801 CGGGCCATTACCAGGCCAAGCAGCGTTGTTGCACTGCACGGCAGATACACTTGCTGATGCGGTGCTGATTACGACCGCTCACGCGTGGCAGCATCAGGG
846 laGlyHisTyrGlnAlaGluAlaAlaLeuLeuGlnCysThrAlaAspThrLeuAlaAspAlaValLeuI leThrThrAlaHisAlaTrpGlnHisGlnGl
4901 GAAAACCTATTATACGCGGAAACCTACCGGATTGATGTAAGTGGTCAAATGGCGATTACCGTTGATGTTGAAGTGGCGAGCGATACACCGCATCCG
879 yLysThrLeuPheI leSerArgLysThrTyrArgI leAspGlySerGlyGlnMetAlal leThrValAspValGluValAlaSerAspThrProHisPro
5001 CGCGGATTGGCCTGAAGTGCAGTGGCGGAAAGCTCAGTGTGACGCTCCCGCGCGTCCACGCGCATCCCGCATCGACCACGCGAAATGGA
913 AlaArgI leGlyLeuAsnCysGlnLeuAlaGlnValAlaGluArgValAsnTrpLeuGlyLeuGlyProGlnGluAsnTyrProAspArgLeuThrAlaA
5101 CCTGTTTGGACCGCTGGATCTGCCATTGTCAGACATGTATACCCGTCAGTCTTCCGAGCGAAAACGGTCTGCGTGGCGGACCGCGAATTGAATTA
946 laCysPheAspArgTrpAspLeuProLeuSerAspMetTyrThrProTyrValPheProSerGluAsnGlyLeuArgCysGlyThrArgGluLeuAsnTy
5201 TGGCCACACCACTGGCGCGGACTTCCAGTTCACATCAGCCGCTACAGTCAACAGCAACTGATGGAAACCAGCCATCGCCATCTGCTGCACGGGAA
979 rGlyProHisGlnTrpArgGlyAspPheGlnPheAsnI leSerArgTyrSerGlnGlnGlnLeuMetGluThrSerHisArgHisLeuLeuAlaGlu
5301 GAAGGCACATGGCTGAATATCGACGGTTCCATATGGGGATTGGTGGCGAGACTCCTGGAGCCCGTCAAGTATCGCGGAAATACAGCTGAGCGCGGTC
1013 GluGlyThrTrpLeuAsnI leAspGlyPheHisMetGlyI leGlyGlyAspAspSerTrpSerProSerValSerAlaGluLeuGlnLeuSerAlaGlyA

EcoRI (5449)

5401 GCTACCATTACCAGTTGGTCTGGTGTCAAAAATAATAATCTAGTCGAGAATTCGCTAGCTCGACATGATAAGATACATTGATGAGTTTGGACAAACCACA
1046 rgTyrHisTyrGlnLeuValTrpCysGlnLys•••
5501 ACTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTAT

5601 AAGCTGCAATAAAACAAGTTAACAAACAATTCATTATTTATGTTTCAGGTTTCAGGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACTCTAC

PacI (5730)

5701 AAATGTGGTAGATCCATTTAAATGTTAAATTAAGTACGATGACCAAAATCCCTTAACGTGAGTTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGAT

5801 CAAAGGATCTTCTTGGATCCTTTTTTCTGCGGTAATCTGCTGCTGCAAAACAAAAAACCCCGTACCAGCGGTGGTTTGTGTTGCCGGATCAAGAG

5901 CTACCAACTCTTTTTCCGAAGGTAAGTGGCTTACGACAGAGCGAGATACAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACT

6001 CTGTAGCACCGCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGCTGCTGCCAGTGGCGATAAGTCTGTCTTACCAGGTTGGACTCAAGACGATA

6101 GTTACCGGATAAGGCGCAGCGTGGGCTGAACGGGGGTTTCGTGCACACAGCCAGCTTGGAGCGAACGACCTACCCGAAGTGGATACCTACAGCGT

6201 GAGCTATGAAAAGCGCCAGCTTCCGAAGGGAGAAAAGCGGCAGGTATCCGGTAAGCGCGAGGTCGGAACAGGAGAGCCAGGAGGGAGCTTCCAG

6301 GGGGAAACGCGCTGGTATCTTTATAGTCTGCTGGGTTTCGCCACCTCTGACTTGAGCGCTGATTTTTGTGATGCTCGTACGGGGGCGGAGCCTATGGAA

PacI (6470)

6401 AAACGCCAGCAACGCGGCTTTTTACGGTTCTCGCCTTTTGTGCGCTTTTGTCCACATGTTCTTAATTAATTTTTCAAAAGTAGTTGACAATTAATC

6501 ATCGGCATAGTATATCGGCATAGTATAATACGACTCACTATAAGGAGGGCCATCATGGCCAAGTTGACCAGTGTGCTGCCAGTGTCCACAGCCAGGGATGT

6601 GGCTGGAGCTGTTGAGTCTGACTGACAGGTTGGGTTCTCCAGAGATTTTGTGGAGGATGACTTTGCAGGTGTGGTCAGAGATGATGTACCCCTGTTCT
16 IAlaGlyAlaValGluPheTrpThrAspArgLeuGlyPheSerArgAspPheValGluAspAspPheAlaGlyValValArgAspAspValThrLeuPhe

6701 ATCTCAGCAGTCCAGGACAGGTGGTGCCTGACAACCCCTGGCTGGGTGAGAGGACTGGATGAGCTGTATGCTGAGTGGAGTGGGTGGTCT
50 I leSerAlaValGlnAspGlnValValProAspAsnThrLeuAlaTrpValTrpValArgGlyLeuAspGluLeuTyrAlaGluTrpSerGluValValS

6801 CCACCAACTCAGGGATGCCAGTGGCCTGCCATGACAGAGATTGGAGAGCGCCCTGGGGGAGAGAGTTTGGCCTGAGAGACCCAGCAGCAACTGTGT
83 erThrAsnPheArgAspAlaSerGlyProAlaMetThrGluI leGlyGluGlnProTrpGlyArgGluPheAlaLeuArgAspProAlaGlyAsnCysVa

PacI (6979)

6901 GCACTTTGTGGCAGAGGAGCAGGACTGAGGATAAGAATTGTAACAAAAAACCCCGCCCGGGGGTTTTTTGTTAATTA
116 IHisPheValAlaGluGluGlnAsp•••